Effectiveness of 225Ac-labeled anti-EGFR radio immunoconjugate in EGFR positive KRAS and BRAF mutant colorectal cancer models

被引：0
|
作者：
Tikum, Anjong [1 ]
Babeker, Hanan [2 ]
Ketchemen, Jessica Pougoue [2 ]
Fonge, Humphrey [2 ]
Njotu, Fabrice Ngoh [2 ]
Nambisan, Anand [2 ]
Doroudi, Alireza [2 ]
机构：
[1] Univ Saskatchewan Bookstore, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P222
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
    F Di Fiore
    F Charbonnier
    B Lefebure
    M Laurent
    F Le Pessot
    P Michel
    T Frebourg
    British Journal of Cancer, 2008, 99 : 551 - 552
  • [32] AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
    Hua Ye
    Yi Liu
    Kefeng Wu
    Hui Luo
    Liao Cui
    Cell Communication and Signaling, 18
  • [33] Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond
    Chu, Edward
    ONCOLOGY-NEW YORK, 2014, 28 (02): : 96 - 96
  • [34] EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
    Uhlyarik, A.
    Piurko, V
    Vizkeleti, L.
    Papai, Zs
    Raso, E.
    Lahm, E.
    Kiss, E.
    Sikter, M.
    Vachaja, J.
    Kenessey, I
    Timar, Jozsef
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1429 - 1434
  • [35] EGFR polymorphism and KRAS mutational status as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study
    Maurel, J.
    Alonso-Espinaco, V.
    Alonso, V.
    Escudero, P.
    Jimeno, M.
    Garcia-Albeniz, X.
    Munoz, J.
    Fernandez-Martos, C.
    Carcereny, E.
    Castellvi-Bel, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
    Ye, Hua
    Liu, Yi
    Wu, Kefeng
    Luo, Hui
    Cui, Liao
    CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [37] Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Sugiyama, Masanori
    Watanabe, Takashi
    ONCOLOGY REPORTS, 2014, 32 (01) : 57 - 64
  • [38] MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
    Mosakhani, Neda
    Lahti, Leo
    Borze, Ioana
    Karjalainen-Lindsberg, Marja-Liisa
    Sundstrom, Jari
    Ristamaki, Raija
    Osterlund, Pia
    Knuutila, Sakari
    Sarhadi, Virinder Kaur
    CANCER GENETICS, 2012, 205 (11) : 545 - 551
  • [39] Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
    Di Fiore, F.
    Charbonnier, F.
    Lefebure, B.
    Laurent, M.
    Le Pessot, F.
    Michel, P.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2008, 99 (03) : 551 - 552
  • [40] KRAS/BRAF Mutation status as a predictive Biomarker for Anti-EGFR Antibody therapy in primary and metastatic colorectal carcinoma.
    Mayer, B.
    Bogner, A.
    Jauch, K. -W
    Singer, T.
    ONKOLOGIE, 2010, 33 : 151 - 151
12345